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Abstract
Background: Early life body size and circulating levels of IGF-1 and IGFBP-3 have been linked to increased risks of
breast and other cancers, but it is unclear whether these exposures act through a common mechanism. Previous
studies have examined the role of IGF-1 and IGFBP-3 genetic variation in relation to adult height and body size,
but few studies have examined associations with birthweight and childhood size.
Methods: We examined whether htSNPs in IGF-1 and the IGFBP-1/IGFBP-3 gene region are associated with the
self-reported outcomes of birthweight, body fatness at ages 5 and 10, and body mass index (BMI) at age 18 among
healthy women from the Nurses’ Health Study (NHS) and NHSII. We used ordinal logistic regression to model odds
ratios (ORs) and 95% confidence intervals (CI) of a one category increase for birthweight and somatotypes at ages 5
and 10. We used linear regression to model associations with BMI at age 18.
Results: Among 4567 healthy women in NHS and NHSII, we observed no association between common IGF-1 or
IGFBP-1/IGFBP-3 SNPs and birthweight, body fatness at ages 5 and 10, or BMI at age 18.
Conclusions: Common IGF-1 and IGFBP-1/IGFBP-3 SNPs are not associated with body size in early life.
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Background
Although early life body size and circulating IGF-1 and
IGFBP-3 have been linked to increased risks of breast
cancer [1-3], it is unclear whether these exposures act
through a common mechanism. We recently reported
that increased birthweight and decreased body size in
youth and adolescence were associated with higher IGF-
1 and IGFBP-3 levels in adulthood [4], suggesting that
early life body size may act on breast cancer risk through
its influence on hormone levels in adulthood. Further,
although genetic variability in IGF-1 and IGFBP-3 has
been linked to their circulating levels [5-7], it is unclear
whether this same variation may influence childhood
body size. Some previous studies of IGF-1 and IGFBP-3
genetic variation in relation to adult height and body
size reported associations with a putative functional
microsatellite polymorphism [6,8-10], but few studies
have examined birthweight [11-13] or childhood body
size [14]. Further, the studies that examined birthweight
examined only the microsatellite polymorphism asso-
ciated with adult height in previous studies [11-13]. In
this study, we investigated potential associations of
haplotype tagging SNPs in IGF-1 and the IGFBP-1/
IGFBP-3 gene region with birthweight, body fatness at
ages 5 and 10, and body mass index (BMI) at age 18, to
determine whether genetic variation could explain the
observed relations of early life body size with circulating
IGF levels in adulthood.
Methods
Study populations
The NHS cohort was established in 1976 among 121,700
US female registered nurses, ages 30 to 55 years; NHSII
was established in 1989 among 116,430 female registered
nurses, ages 25 to 42 years. All women completed an ini-
tial questionnaire about their lifestyle factors, health
behaviors, and medical history, and have been followed
biennially by questionnaire. From 1989 to 1990, 32,826
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samples and completed a short questionnaire [15]. Blood
was processed and separated into plasma, red blood cell,
and white blood cell components. From 2002 to 2004,
kits to collect buccal cells were received from 33,040
NHS women (ages 54–84) had not previously provided a
blood sample and had completed the 2000 question-
naire. DNA was extracted and purified upon sample
receipt.
Between 1996 and 1999, 29,611 NHSII participants
(ages 32 to 54 years) provided blood samples and com-
pleted a short questionnaire [16]. Briefly, premenopausal
women, either provided a luteal blood sample 7 to 9 days
before the anticipated start of their next cycle
(n=18,521) or a single 30-mL untimed blood sample
(n=11,090). NHSII samples were processed identically
to the NHS samples. All study participants provided
informed consent. This study was approved by the Com-
mittee on the Use of Human Subjects in Research at the
Brigham and Women’s Hospital and the Harvard School
of Public Health (Boston, MA).
The current analysis includes women with available
DNA who were controls from 7 nested case–control
studies of IGF-1 and IGBFP-3 SNPs and risk of various
chronic diseases, including benign breast disease [17],
breast cancer [5], endometrial cancer [18], myeloma
[19], and ovarian cancer [20] (N=4567).
Body size and covariate information
Body size and covariate information was obtained from
the questionnaire completed at sample collection and
biennial study questionnaires. Birthweight was collected
in 1992 (NHS) and 1991 (NHSII). In the NHS, the cor-
relation between the participant’s self-reported birth-
weight and that reported by her mother was 0.77 [2]. In
1988 (NHS) and 1989 (NHSII), women were asked to
choose one of nine diagrams (somatotypes) [21] that
best depicted their body fatness at ages 5 and 10, with
higher levels indicating larger body size. Among older
women (aged 71–76) in another study population, the
correlations between recalled somatotype and measured
BMI were 0.57 at age 5 and 0.70 at age 10; the correla-
tions were similar after controlling for current BMI [22].
BMI at blood draw and at age 18 (asked in 1980 for
NHS and in 1989 for NHS2) were calculated as self-
reported weight in kilograms divided by self-reported
height (collected at baseline) in meters squared.
We considered a woman to be premenopausal at sam-
ple collection if (1) she gave a luteal sample (NHSII
only), (2) her periods had not ceased, or (3) she had at
least one ovary and was 47 years or younger (nonsmo-
kers) or 45 years or younger (smokers). We considered a
woman to be postmenopausal if (1) her natural men-
strual periods had ceased permanently, (2) she had a
bilateral oophorectomy, or (3) she had at least one ovary
and was 56 years or older (nonsmokers) or 54 years or
older (smokers). The age cutoffs represent the age when
90% of women with intact ovaries in the cohorts were
premenopausal or postmenopausal, respectively. The
remaining women, most of whom had a simple hysterec-
tomy and were 48 to 55 years old, were considered to be
of unknown menopausal status.
SNP selection and genotyping
SNP selection and genotyping have been described pre-
viously [5,17,19,20]. Briefly, haplotype tagging SNPs
(htSNPs) were identified by the Breast and Prostate Can-
cer Cohort Consortium (BPC3).
a In IGF-1, 154 SNPs (56
SNPs in IGFBP-1/IGFBP-3) were genotyped in a panel
representing several racial groups. Of these, 64 IGFBP-1
and 36 IGFBP-1/IGFBP-3 SNPs passed quality control
and were confirmed to be SNPs. From these remaining
SNPs, the expectation-maximization algorithm was used
to select 14 IGF-1 and 12 IGFBP-1/IGFBP-3 SNPs that
were predicted to tag the common haplotypes in Cauca-
sian populations (rh
2>0.85). Four additional SNPs in
IGFBP-1/IGFBP-3 were included in the BPC3 genotyp-
ing, in which the NHS and NHSII nested case–control
samples for breast cancer were included.
DNA extraction and genotyping were performed at
the Dana–Farber Cancer Institute/Harvard Cancer Cen-
ter High Throughput Genotyping Core, a unit of the
Harvard–Partners Genotyping Facility. DNA was extracted
using a QIAamp 96 DNA Blood Kit (Qiagen). Genotyping
assays for the 22 SNPs were performed by the 5’ nuclease
assay (Taqman) on the Applied Biosystems Prism 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA). Taqman primers, probes and conditions for
genotyping assays are available upon request. Laboratory
personnel were blinded to case–control status, and dupli-
cate samples (10% of sample size) were inserted to validate
genotyping procedures. More than 95% of the samples
were successfully genotyped for each polymorphism and
there were no discordant quality control sets.
Statistical analysis
We used ordinal logistic regression models to analyze
the association between IGF-1 and IGFBP-1/IGFBP-3
SNPs and body size (birthweight, somatotypes at ages 5
and 10, and average somatotype at ages 5 and 10). Birth-
weight was categorized as <5.5 lbs, 5.5-6.9 lbs, 7–8.4 lbs,
8.5-9.9 lbs, or 10+ lbs, based on the questionnaire cat-
egories. As a secondary analysis, we examined the asso-
ciations with low birth weight (<5.5 lbs) vs. all others
using logistic regression. Somatotypes at ages 5 and 10
were categorized as diagram 1, 2, 3, 4, and 5+. To assess
the fit of ordinal logistic regression models, we conducted
the score test for proportional odds. Since BMI at age 18
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assess the associations between IGF variability and this
outcome. SNPs were included in the model as ordinal
terms with values from 0 to 2 (i.e. as one variable coded 0
for the homozygous major allele genotypes, 1 for heterozy-
gous genotypes, and 2 for homozygous variant genotypes).
Additionally, we combined SNPs using two methods. First,
11 SNPs (rs1520220, rs35767, rs7965399, rs2195239,
rs2946834, rs2854744, rs2854746, rs3110697, rs2270628,
rs2960436, rs2132570) associated with circulating IGF-1
or IGFBP-3 levels previously [5,7,23] were combined to
make a SNP score. The allele that was associated with
higher levels was considered the “risk” allele. Having one
copy of the risk allele added one to the score; two copies
added two to the score. Second, we used reduced rank re-
gression [24] to construct a score of IGF-1 and IGFBP-3
SNPs that explained variability in measured plasma IGF-1
and IGFBP-3 in the NHS and NHSII participants who had
both plasma levels and genotypes. We applied the scores
to all women with genotypes and assessed associations
with both scores using ordinal logistic regression (for
birthweight and somatotypes) or linear regression (for
BMI at age 18) as described above.
All models were adjusted for age at blood draw or
cheek cell collection, menopausal status at collection
and reference date, postmenopausal hormone use at
collection and reference date, and DNA source (blood
vs. cheek). The two cohorts were analyzed separately
and combined using random effects meta-analysis. All
p-values were two-sided and considered statistically sig-
nificant if ≤0.05. Ordinal logistic regression analyses
were conducted in STATA 11.0 (STATACorp, College
Station, TX). Linear regression analysis and meta-
analyses were conducted using SAS version 9.1 (SAS
Institute, Cary, NC).
Results
Among genotyped NHS participants, 12% had a birth-
weight <5.5 lbs and 3% had a birthweight of 10 lbs or
more (Table 1). Mean somatotypes at ages 5 and 10 were
2.3 and 2.5, respectively, and mean BMI at age 18 was
21.2. Among genotyped NHSII participants, 9% had a
birthweight <5.5 lbs and 1% had a birthweight of 10 lbs
or more. Mean somatotypes at ages 5 and 10 were 2.5
and 2.8, respectively, and mean BMI at age 18 was 21.1.
NHS participants were older than NHSII participants at
blood draw/buccal cell collection and were more likely
to be postmenopausal. 10% of NHS samples were from
buccal cell samples; all other participants had a blood
sample.
In general, there was no association between genetic vari-
ability in IGF-1 or IGFBP-1/IGFBP-3 a n db o d ys i z ea tb i r t h
or in childhood (Table 2). IGF-1 rs35767 was associated
with decreased BMI at age 18 (p=0.03) and rs5742665 was
associated with a slight increase in BMI at age 18 (p=0.04).
We also observed significant associations with low birth-
weight (data not shown), however, none of these associa-
tions remained significant after Bonferroni correction.
Although Table 2 shows the associations for average som-
atotype at ages 5 and 10, results were similar when somato-
types at ages 5 and 10 were analyzed separately (data not
shown). There was no association with either of the SNP
scores after adjustment for multiple comparisons (data not
shown).
Discussion
In this study of 4567 women from the NHS and
NHSII cohorts, we observed no association between
genetic variability in IGF-1 and IGFBP-1/IGFBP-3 and
birth weight or body fatness in childhood and adoles-
cence. Previous studies of the association between
IGF-1 or IGFBP-1/IGFBP-3 and early life body size
Table 1 Age standardized characteristics at blood draw/
buccal cell collection and control selection
NHSI NHSII
(n=3499) (n=1068)
Age at blood draw/buccal cell
collection, mean (SD)
a
59.6 (7.7) 44.9 (4.3)
Somatotype at age 5
b, mean (SD) 2.3 (1.3) 2.5 (0.9)
Somatotype at age 10
b, mean (SD) 2.5 (1.3) 2.8 (1.0)
BMI at age 18, mean (SD) 21.2 (2.7) 21.1 (2.2)
Birthweight
b, N (%)
<5.5 lbs 329 (12.0) 84 (8.8)
10+ lbs 79 (2.9) 12 (1.3)
DNA from blood, N (%) 3132 (89.5) 1068 (100)
Menopausal status/Post-menopausal
hormone (PMH) use at blood
draw/buccal cell collection
b, N (%)
Premenopausal 764 (24.0) 680 (68.2)
Postmenopausal-PMH non-user 1574 (49.5) 136 (13.6)
Postmenopausal-PMH user 843 (26.5) 182 (18.2)
Menopausal status/Post-menopausal
hormone (PMH) use at reference
date
b, N (%)
Premenopausal 508 (16.0) 479 (47.7)
Postmenopausal-PMH non-user 1479 (46.8) 37 (3.7)
Postmenopausal-PMH user 1171 (37.1) 487 (48.6)
aValue is not age-standardized.
bCalculated among those with known values.
NHS:7% were missing information on somatotype at age 5, 6% were missing
information on somatotype at age 10, and 22% were missing information on
birthweight. 9% were missing menopausal status at blood draw and 9% were
missing menopausal status at selection.
NHSII:1% were missing information on somatotype at age 5, 1% were missing
information on somatotype at age 10, and 11% were missing information on
birthweight. 7% were missing menopausal status at blood draw and 6% were
missing menopausal status at selection.
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polymorphism in the IGF-1 promoter. This poly-
morphism has been associated with increased weight,
BMI, and fat mass in a Dutch cohort of children ages
11 to 13, particularly among female children [14]. Fur-
ther, this polymorphism was associated with decreased
birthweight [11] in one study, but this was not con-
firmed in two other studies [12,13]. We did not
genotype this polymorphism in our study, but instead
focused on htSNPs that capture genetic variability
across the IGF-1 and IGFBP-1/IGFBP-3 loci.
Two studies have examined tagSNPs in these genes in
relation to adult height in Caucasians [8,9]. The first [8]
examined 13 SNPs in IGF-1 and 1 SNP in IGFBP-3 in a
panel of 2189 individuals above the 90
th percentile or
below the 10
th percentile of height. Any associations
Table 2 Associations between SNPs in IGF-1 and IGFBP-3 and body size in early life
a
Birthweight Average somatotype BMI at age 18
at ages 5 and 10
Gene SNP MAF OR 95% CI p OR 95% CI p β SE p
IGF-1 rs1996656 0.18 0.96 (0.80-1.15) 0.64 1.03 (0.93-1.14) 0.57 −0.0068 0.0050 0.17
rs4764695 0.50 1.06 (0.97-1.16) 0.16 1.01 (0.93-1.10) 0.75 0.0017 0.0044 0.70
rs4764876 0.26 0.90 (0.76-1.08) 0.27 1.02 (0.93-1.11) 0.65 0.0045 0.0032 0.16
rs2946834 0.32 0.93 (0.85-1.02) 0.12 1.00 (0.92-1.08) 0.91 0.0020 0.0029 0.49
rs1520220 0.18 0.93 (0.83-1.04) 0.18 0.98 (0.87-1.10) 0.72 −0.0037 0.0036 0.30
rs1549593 0.13 1.02 (0.89-1.16) 0.79 0.95
b (0.72-1.26) 0.73 −0.0007 0.0063 0.91
rs5742665 0.13 0.98 (0.83-1.15) 0.83 1.00 (0.90-1.13) 0.94 0.0103 0.0051 0.04
rs2373722 0.07 0.91 (0.77-1.08) 0.28 0.88 (0.71-1.08) 0.21 −0.0027 0.0053 0.61
rs10735380 0.27 0.93 (0.83-1.04) 0.21 0.98 (0.90-1.06) 0.58 −0.0031 0.0032 0.34
rs2195239 0.23 0.94 (0.83-1.08) 0.39 1.01 (0.92-1.10) 0.85 −0.0043
b 0.0080 0.59
rs1019731 0.13 1.06 (0.93-1.21) 0.35 1.09 (0.98-1.23) 0.12 0.0021 0.0041 0.61
rs12821878 0.22 1.11 (0.99-1.23) 0.06 1.09 (0.94-1.28) 0.26 0.0030 0.0034 0.38
rs35767 0.16 0.98 (0.87-1.12) 0.81 0.89 (0.77-1.04) 0.14 −0.0080 0.0038 0.03
rs7965399 0.04 1.01 (0.75-1.38) 0.92 0.90 (0.75-1.09) 0.30 −0.0026 0.0067 0.70
IGFBP-1/IGFBP-3 rs4619 0.35 1.02 (0.91-1.14) 0.75 0.99 (0.84-1.17) 0.93 −0.0018 0.0029 0.54
rs2201638 0.03 0.92 (0.57-1.48) 0.73 1.05 (0.71-1.56) 0.80 0.0257 0.0156 0.10
rs1065780 0.38 1.02 (0.93-1.11) 0.74 1.02 (0.94-1.11) 0.55 −0.0002 0.0039 0.95
rs1553009 0.20 1.04 (0.94-1.17) 0.44 1.10 (1.00-1.21) 0.06 0.0042 0.0035 0.23
rs35539615 0.23 0.98 (0.87-1.10) 0.71 0.95 (0.85-1.06) 0.34 0.0018 0.0036 0.62
rs1908751 0.30 0.97 (0.88-1.07) 0.56 0.95 (0.87-1.03) 0.20 0.0061 0.0031 0.05
rs4988515 0.04 1.13 (0.91-1.40) 0.27 1.08 (0.89-1.33) 0.43 −0.0018 0.0111 0.87
rs10228265 0.31 0.94 (0.86-1.03) 0.19 0.98 (0.90-1.06) 0.59 −0.0043 0.0030 0.15
rs2270628 0.19 1.01 (0.84-1.23) 0.89 0.96 (0.87-1.06) 0.38 −0.0052 0.0064 0.42
rs6670 0.21 0.93 (0.84-1.03) 0.18 0.99 (0.90-1.09) 0.82 0.0033 0.0043 0.44
rs2453839 0.20 0.97 (0.86-1.08) 0.54 1.02 (0.84-1.25) 0.84 0.0113
b 0.0086 0.19
rs3110697 0.42 0.98 (0.90-1.07) 0.63 0.94 (0.82-1.09) 0.43 −0.0055
b 0.0081 0.50
rs2854746 0.40 1.09 (1.00-1.20) 0.06 1.02 (0.94-1.10) 0.65 0.0003 0.0029 0.91
rs2854744 0.47 1.09 (0.90-1.32) 0.39 1.01 (0.94-1.10) 0.73 −0.0029 0.0032 0.37
rs2132570 0.22 0.96 (0.81-1.15) 0.69 0.92 (0.83-1.03) 0.16 −0.0048 0.0049 0.33
rs2960436 0.46 1.12 (0.93-1.34) 0.25 0.99 (0.91-1.08) 0.89 −0.0023 0.0046 0.61
aBirthweight was categorized as <5.5 lbs, 5.5-6.9 lbs, 7-8.4 lbs, 8.5-9.9 lbs, and 10+ lbs. Somatotypes at age 5 and 10 were categorized as 1,2,3,4,5+. BMI at age 18
was log-transformed and continuous. Birthweight and somatotypes at age 5 and 10 were analyzed in ordinal logistic regression models; BMI at age 18 was
analyzed in a linear regression model. All models were adjusted for age at blood draw/cheek collection, menopausal status at blood draw/cheek collection and
case selection, post-menopausal hormone use at blood draw/cheek collection and control selection, and DNA source (NHS only).
bThe NHS and NHSII cohorts were combined using meta-analysis techniques. These estimates had P-het <0.05, indicating heterogeneity between the cohorts.
Abbreviations: SNP: single nucleotide polymorphism; IGF-1: insulin-like growth factor 1; IGFBP-3: insulin-like growth factor binding protein 3; BMI: body mass
index; MAF: minor allele frequency; OR: Odds Ratio; CI: confidence interval; SE: standard error.
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study populations. No associations were noted this
study. The second study [9] used a family-based ap-
proach and reported that two SNPs, rs5742694 and
rs2033178, were associated with adult height, particu-
larly among females. We did not genotype these SNPs in
our study. However, rs2033178 is in perfect LD with
rs2373722, which we did assess. We observed no asso-
ciations between this SNP and any of the body size mea-
sures in our study.
An important limitation of this study is that we did
not genotype the IGF-1 promoter microsatellite poly-
morphism, which has been associated with circulating
IGF-1 levels [6,10]. However, most previous studies have
not observed this polymorphism to be associated with
childhood body size. Thus, we focused on genetic vari-
ability across the IGF-1 and IGFBP-1/IGFBP-3 loci. Fur-
ther, our measures of birthweight and childhood size are
based on self-report. However, we have shown previ-
ously that these measures are highly correlated with ac-
tual size [2,22], indicating that they are reliable
measures. A major strength of this study is that we had
adequate power to detect even modest associations. For
example, for birthweight, for which we had the lowest
number of study participants (N=3640), we had over
80% power to detect modest associations (β=0.0033) for
minor allele frequencies as low as 0.04 at α=0.001
(Bonferroni corrected for multiple comparisons).
Conclusions
This study comprehensively examined genetic variation
in IGF-1 and IGFBP-1/IGFBP-3 in relation to birth-
weight and body size in childhood and adolescence in
over 4200 women. We observed no associations between
IGF-1 or IGFBP-1/IGFBP-3 SNPs and body size, sug-
gesting that previously observed associations between
childhood body size and adult IGF-1 levels likely are not
due to underlying genetic variability in IGF-related
genes. However, the lack of association should be con-
firmed in studies which directly measured birthweight
and body size at various ages in youth and adolescence.
Endnote
a http://cgf1.nci.nih.gov/cohort.cfm.
Abbreviations
BMI: Body mass index; CI: Confidence interval; IGF-1: Insulin-like growth
factor 1; IGFBP-1: Insulin-like growth factors binding protein 1; IGFBP-
3: Insulin-like growth factors binding protein 3; NHS: Nurses’ Health Study;
NHSII: Nurses’ Health Study II; OR: Odds ratio; SNP: Single nucleotide
polymorphism.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
EP carried out the data analysis and drafted the manuscript. ST helped
design the study, oversaw the data analysis, and helped to write the
manuscript. SH contributed to study design and provided feedback on
results. HB conceived of the study, obtained funding for the study, and
contributed to manuscript preparation. All authors read and approved the
final manuscript.
Acknowledgements
This research was supported by National Cancer Institute grants R03
CA132182, T32 CA009001, P01 CA87969, R01 CA50385, U01 CA49449, and
R01 CA67262. We thank the following state cancer registries for their help:
AL, AZ, AR, CA, CO, CT, DE, FL, GA, ID, IL, IN, IA, KY, LA, ME, MD, MA, MI, NE,
NH, NJ, NY, NC, ND, OH, OK, OR, PA, RI, SC, TN, TX, VA, WA, and WY.
Author details
1Department of Medicine, Channing Laboratory, Brigham and Women's
Hospital and Harvard Medical School, 181 Longwood Ave, Boston, MA 02115,
USA.
2Department of Epidemiology, Harvard School of Public Health, Boston,
MA 02115, USA.
3Division of General Medicine and Primary Care, Brigham
and Women’s Hospital, Boston, MA 02115, USA.
4Department of Medicine,
Harvard Medical School, Boston, MA 02115, USA.
5Department of Public
Health, University of Massachusetts Amherst, Amherst, MA 02115, USA.
Received: 25 January 2012 Accepted: 16 July 2012
Published: 15 August 2012
References
1. Baer HJ, Hankinson SE, Tworoger SS: Body size in early life and risk of
epithelial ovarian cancer: results from the Nurses' Health Studies. Br J
Cancer 2008, 99(11):1916–1922.
2. Michels KB, Trichopoulos D, Robins JM, Rosner BA, Manson JE, Hunter DJ,
Colditz GA, Hankinson SE, Speizer FE, Willett WC: Birthweight as a risk
factor for breast cancer. Lancet 1996, 348(9041):1542–1546.
3. Key TJ, Appleby PN, Reeves GK, Roddam AW: Insulin-like growth factor 1
(IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled
individual data analysis of 17 prospective studies. Lancet Oncol 2010,
11(6):530–542.
4. Poole EM, Tworoger SS, Hankinson SE, Schernhammer ES, Pollak MN,
Baer HJ: Body size in early life and adult IGF-1 and IGFBP-3 levels. Am J
Epidemiol 2011, 174(6):642–651.
5. Patel AV, Cheng I, Canzian F, Le Marchand L, Thun MJ, Berg CD, Buring J,
Calle EE, Chanock S, Clavel-Chapelon F, et al: IGF-1, IGFBP-1, and IGFBP-3
polymorphisms predict circulating IGF levels but not breast cancer risk:
findings from the Breast and Prostate Cancer Cohort Consortium (BPC3).
PLoS One 2008, 3(7):e2578.
6. Fehringer G, Ozcelik H, Knight JA, Paterson AD, Boyd NF: Association
between IGF1 CA microsatellites and mammographic density,
anthropometric measures, and circulating IGF-I levels in premenopausal
Caucasian women. Breast Cancer Res Treat 2009, 116(2):413–423.
7. D'Aloisio AA, Schroeder JC, North KE, Poole C, West SL, Travlos GS, Baird DD:
IGF-I and IGFBP-3 polymorphisms in relation to circulating levels among
African American and Caucasian women. Cancer Epidemiol Biomarkers Prev
2009, 18(3):954–966.
8. Lettre G, Butler JL, Ardlie KG, Hirschhorn JN: Common genetic variation in
eight genes of the GH/IGF1 axis does not contribute to adult height
variation. Hum Genet 2007, 122(2):129–139.
9. Yang TL, Xiong DH, Guo Y, Recker RR, Deng HW: Comprehensive
association analyses of IGF1, ESR2, and CYP17 genes with adult height
in Caucasians. Eur J Hum Genet 2008, 16(11):1380–1387.
10. Fehringer G, Ozcelik H, Knight JA, Paterson AD, Dite GS, Giles GG,
Southey MC, Andrulis IL, Hopper JL, Boyd NF: Family-based association
study of IGF1 microsatellites and height, weight, and body mass index.
J Hum Genet 2010, 55(4):255–258.
11. Vaessen N, Janssen JA, Heutink P, Hofman A, Lamberts SW, Oostra BA,
Pols HA, van Duijn CM: Association between genetic variation in the gene
for insulin-like growth factor-I and low birthweight. Lancet 2002,
359(9311):1036–1037.
12. Frayling TM, Hattersley AT, McCarthy A, Holly J, Mitchell SM, Gloyn AL,
Owen K, Davies D, Smith GD, Ben-Shlomo Y: A putative functional
polymorphism in the IGF-I gene: association studies with type 2
Poole et al. BMC Public Health 2012, 12:659 Page 5 of 6
http://www.biomedcentral.com/1471-2458/12/659diabetes, adult height, glucose tolerance, and fetal growth in U.K.
populations. Diabetes 2002, 51(7):2313–2316.
13. Geelhoed JJ, Mook-Kanamori DO, Witteman JC, Hofman A, van Duijn CM,
Moll HA, Steegers EA, Hokken-Koelega AC, Jaddoe VW: Variation in the
IGF1 gene and growth in foetal life and infancy. The Generation R Study.
Clin Endocrinol (Oxf) 2008, 68(3):382–389.
14. Voorhoeve PG, van Rossum EF, Te Velde SJ, Koper JW, Kemper HC,
Lamberts SW, de Waal HA: Association between an IGF-I gene
polymorphism and body fatness: differences between generations. Eur J
Endocrinol 2006, 154(3):379–388.
15. Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ,
Longcope C, Speizer FE: Alcohol, height, and adiposity in relation to
estrogen and prolactin levels in postmenopausal women. J Natl Cancer
Inst 1995, 87(17):1297–1302.
16. Tworoger SS, Sluss P, Hankinson SE: Association between plasma prolactin
concentrations and risk of breast cancer among predominately
premenopausal women. Cancer Res 2006, 66(4):2476–2482.
17. Su X, Colditz GA, Willett WC, Collins LC, Schnitt SJ, Connolly JL, Pollak MN,
Rosner B, Tamimi RM: Genetic variation and circulating levels of IGF-I and
IGFBP-3 in relation to risk of proliferative benign breast disease. Int J
Cancer 2010, 126(1):180–190.
18. McGrath M, Lee IM, Buring J, De Vivo I: Common genetic variation within
IGFI, IGFII, IGFBP-1, and IGFBP-3 and endometrial cancer risk. Gynecol
Oncol 2011, 120(2):174–178.
19. Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P,
Mitsiades C, Anderson KC, Colditz GA: Insulin-like growth factor-1- and
interleukin-6-related gene variation and risk of multiple myeloma. Cancer
Epidemiol Biomarkers Prev 2009, 18(1):282–288.
20. Terry KL, Tworoger SS, Gates MA, Cramer DW, Hankinson SE: Common
genetic variation in IGF1, IGFBP1 and IGFBP3 and ovarian cancer risk.
Carcinogenesis 2009, 30(12):2042–2046.
21. Stunkard A, Sorenson T, Schulsinger F: Use of the Danish Adoption
Register for the study of obesity and thinness.I nThe genetics of
neurological and psychiatric disorders. Edited by Kety S, Rowland L, Sidman S,
Mathysee S. New York: Raven; 1983.
22. Must A, Willett WC, Dietz WH: Remote recall of childhood height, weight,
and body build by elderly subjects. Am J Epidemiol 1993, 138(1):56–64.
23. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S,
Boillot C, Monnier S, Chajes V, et al: Polymorphisms of genes coding for
insulin-like growth factor 1 and its major binding proteins, circulating
levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC
study. Br J Cancer 2006, 94(2):299–307.
24. Hoffmann K, Schulze MB, Schienkiewitz A, Nothlings U, Boeing H:
Application of a new statistical method to derive dietary patterns in
nutritional epidemiology. Am J Epidemiol 2004, 159(10):935–944.
doi:10.1186/1471-2458-12-659
Cite this article as: Poole et al.: Genetic variability in IGF-1 and IGFBP-3
and body size in early life. BMC Public Health 2012 12:659.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Poole et al. BMC Public Health 2012, 12:659 Page 6 of 6
http://www.biomedcentral.com/1471-2458/12/659